Congress to Mylan: Tell us more
October 04, 2016 at 08:23 AM EDT
The controversy over pricing of the anti-allergy medication EpiPen continues to dog Canonsburg's Mylan NV (Nasdaq: MYL).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.